Events

Avis De Sécurité sur LotusTM Valve System Model: H749LTV230, H749LTV250, H749LTV270; catalogue: LTV23, LTV25, LTV27

Selon Swiss Agency for Therapeutic Products, ce/cet/cette avis de sécurité concerne un dispositif en/au/aux/à Switzerland qui a été fabriqué par Boston Scientific Corporation.

Qu'est-ce que c'est?

Les avis de sécurité sont des communications que les fabricants de dispositifs médicaux ou leurs représentants font parvenir en particulier aux travailleurs du secteur médical, mais aussi aux utilisateurs de ces dispositifs. Les avis de sécurité concernent les actions entreprises quant aux dispositifs présents sur le marché et peuvent inclure des rappels et des alertes.

En savoir plus sur les données ici
  • Type d'événement
    Field Safety Notice
  • ID de l'événement
    Vk_20170220_11
  • Date de publication de l'événement
    2017-02-27
  • Pays de l'événement
    Switzerland
  • Source de l'événement
    SATP
  • URL de la source de l'événement
    https://fsca.swissmedic.ch/mep/#?q=Vk_20170220_11
  • Notes / Alertes
    The data from Switzerland is current through March 2018. All of the data comes from Swiss Agency for Therapeutic Products, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Switzerland.
  • Notes supplémentaires dans les données

Device

LotusTM Valve System Model: H749LTV230, H749LTV250, H749LTV270; catalogue: LTV23, LTV25, LTV27
  • Modèle / numéro de série
    all
  • Description du dispositif
    MD: Transcatheter heart valve bioprosthesis, stent-like framework
  • Manufacturer
    Boston Scientific Corporation

Manufacturer

Boston Scientific Corporation
  • Société-mère du fabricant (2017)
    Boston Scientific
  • Commentaire du fabricant
    “We take a patient-first approach to assessing the applicability of every recall and communicate to regulatory bodies in all geographies where the recalled device is sold,” Boston Scientific said in a statement to ICIJ. “We have coordinated several recalls across many countries in a timely manner,” the company said, adding that it complies with all national laws, which can often vary and require different processes for reporting information or taking action on recalls. The company said it uses a rigorous and uniform process to take action on recalls and that “when we initiate a field action (e.g. recall, safety alert), every customer who has received an affected product receives a communication that includes a letter for the physician.”
  • Source
    SATP